Literature DB >> 25081575

Development trends for generation of single-chain antibody fragments.

Safar Farajnia1, Vahideh Ahmadzadeh, Asghar Tanomand, Kamal Veisi, Shiva Ahdi Khosroshahi, Leila Rahbarnia.   

Abstract

Recombinant antibodies are increasingly being employed as therapeutic agents especially in combination with anti-cancer drugs. The single-chain antibody fragments are small antigen-binding proteins which provide the most commonly used antibody formats for diagnostic and therapeutic purposes. These antibody fragments have more rapid tumor penetration and clearance from the serum relative to full-length monoclonal antibodies. There are in vitro antibody-display technologies such as phage display, cell surface display, ribosome display and mRNA display that can be used to isolate high specificity and affinity single-chain antibodies against a wide variety of targets. We review these strategies for generation of stable and active antibody fragments in the present article.

Entities:  

Keywords:  Display methods; improved stability; single-chain antibody fragments

Mesh:

Substances:

Year:  2014        PMID: 25081575     DOI: 10.3109/08923973.2014.945126

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  15 in total

Review 1.  CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.

Authors:  Yaghoub Safdari; Vahideh Ahmadzadeh; Safar Farajnia
Journal:  Invest New Drugs       Date:  2016-04-13       Impact factor: 3.850

Review 2.  Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.

Authors:  Christian Fercher; Sahar Keshvari; Michael A McGuckin; Ross T Barnard
Journal:  Exp Biol Med (Maywood)       Date:  2017-12-19

3.  Anti-ABCG2 scFv antibody of lung adenocarcinoma increases chemosensitivity and induces apoptosis through the activation of mitochondrial pathway.

Authors:  Wen-Si Zhao; Yi Luo; Bo-Yi Li; Han-Jing Zhou; Tao Zhang
Journal:  Am J Cancer Res       Date:  2016-05-01       Impact factor: 6.166

Review 4.  A new age for biomedical applications of Ribosome Inactivating Proteins (RIPs): from bioconjugate to nanoconstructs.

Authors:  Elio Pizzo; Antimo Di Maro
Journal:  J Biomed Sci       Date:  2016-07-20       Impact factor: 8.410

5.  High-efficiency antibody discovery achieved with multiplexed microscopy.

Authors:  Shelley Mettler Izquierdo; Stephanie Varela; Minha Park; Ellen J Collarini; Daniel Lu; Shreya Pramanick; Joseph Rucker; Lucia Lopalco; Rob Etches; William Harriman
Journal:  Microscopy (Oxf)       Date:  2016-04-21       Impact factor: 1.571

6.  Ribosome display for the rapid generation of high-affinity Zika-neutralizing single-chain antibodies.

Authors:  Adinarayana Kunamneni; Chunyan Ye; Steven B Bradfute; Ravi Durvasula
Journal:  PLoS One       Date:  2018-11-16       Impact factor: 3.240

7.  Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer.

Authors:  Sheng-Jia Shi; Li-Juan Wang; Dong-Hui Han; Jie-Heng Wu; Dian Jiao; Kai-Liang Zhang; Jiang-Wei Chen; Yu Li; Fa Yang; Jing-Liang Zhang; Guo-Xu Zheng; An-Gang Yang; Ai-Zhi Zhao; Wei-Jun Qin; Wei-Hong Wen
Journal:  Theranostics       Date:  2019-02-07       Impact factor: 11.556

8.  Single-Chain Variable Fragment Antibody of Vascular Cell Adhesion Molecule 1 as a Molecular Imaging Probe for Colitis Model Rabbit Investigation.

Authors:  Chunbao Liu; Jun Zhou; Xiaojie Cheng; Liang Xia; Junfen Zhou; Shufang Xu; Yichun Wang; Yongxue Zhang; Diyu Lu
Journal:  Contrast Media Mol Imaging       Date:  2019-01-20       Impact factor: 3.161

Review 9.  Ribosome Display Technology: Applications in Disease Diagnosis and Control.

Authors:  Adinarayana Kunamneni; Christian Ogaugwu; Steven Bradfute; Ravi Durvasula
Journal:  Antibodies (Basel)       Date:  2020-06-27

10.  Effects of different interchain linkers on biological activity of an anti-prostate cancer single-chain bispecific antibody.

Authors:  Chao-hui Hao; Qian-he Han; Zhong-jie Shan; Jian-ting Hu; Nan Zhang; Xue-pei Zhang
Journal:  Theor Biol Med Model       Date:  2015-08-06       Impact factor: 2.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.